How can diplomats and scientists work together to make political change that improves global health and strengthens international relations? Article by Ambassador Jimmy Kolker and Mr Ashraf Abdelghany.
Read more
For some cancers, initial treatment with chemotherapy brings positive, but only temporary, results: tumours shrink, but then rebound as the cancer becomes drug-resistant. This pattern of remission-resistance-relapse is particularly true for pancreatic cancer, an aggressive disease in which early success is often countered by eventual disease progression.
The thalassemia syndromes are genetic disorders characterized by absent or deficient synthesis of one or more of the normal globin chains. Biotechnologist Osama Atif provides an overview of these gentic disorders.
White blood cells known as B cells have been shown to be effective for predicting which cancer patients will respond to immune checkpoint blockade (ICB) therapy.
According to the paper now available online, TP53 is the most frequently mutated gene in triple negative breast cancer, meaning it is fuelling the growth of this aggressive form of breast cancer. However, the problem with trying to target mutated TP53, specifically, is that it is not a druggable target, because of its potential toxicity – or ability to kill – nearby healthy cells.
Vasopressors are medications that causes vasoconstriction; some of them have additional inotropic effect. By maintaining end-organ perfusion; the role of vasopressors remains critical to prevent irreversible organ injury and failure, and their use is usually accompanied by fluid resuscitation for adequate patient outcomes. Vasopressor agents are used clinically in the treatment of arterial hypotension in shock states. Shock is best defined as inadequate blood flow to meet the metabolic needs of the tissues. The most common reasons for shock are the cardiac output is low relative to the global demand, despite increased O2 extraction by the tissues; or perfusion pressure is inadequate such that blood flow distribution to metabolically active tissues is inadequate, despite an otherwise adequate cardiac output.
Dr Bedei, Dr Delisle, Dr Hofmann-Werther, and Dr Pour Mirza highlight how to treat abnormal menstrual bleeding in adolescents.
Deborah Kobewka, Managing Director of Healthcare UK, shares insights from the UK’s National Health Service, on how healthcare authorities and operators in the Gulf states can build, design, and operate the ‘Hospital of the Future’.
Dr Ivonne Bedei, Dr Amelie Hofmann-Werther, and Dr Afshin Pour Mirza provide detailed information about the prenatal diagnosis of Turner syndrome.
